Previous close | 81.01 |
Open | 80.17 |
Bid | 79.26 x 0 |
Ask | 79.53 x 0 |
Day's range | 80.17 - 80.17 |
52-week range | 58.34 - 88.06 |
Volume | |
Avg. volume | 1 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
NYON, Switzerland, May 08, 2024--Edwards Lifesciences today announced the European launch of the SAPIEN 3 Ultra RESILIA valve, the only transcatheter aortic heart valve to incorporate the company’s breakthrough RESILIA tissue technology, designed to extend the valve’s durability.*
IRVINE, Calif., April 25, 2024--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2024.
IRVINE, Calif., April 18, 2024--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results.